Seres Therapeutics (MCRB) Liabilities from Discontinued Operations (2023)
Seres Therapeutics (MCRB) posted Liabilities from Discontinued Operations of 109427000.0 for Q4 2023.
Seres Therapeutics (MCRB) Liabilities from Discontinued Operations (2023) Analysis & Trends
Seres Therapeutics has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 109427000.0 in Q4 2023.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 109427000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 109427000.0 (changed N/A YoY) and the FY2023 annual result came in at 109427000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at 109427000.0 in Q4 2023 per MCRB's latest filing.
- Over five years, Liabilities from Discontinued Operations peaked at 109427000.0 in Q4 2023 and troughed at 109427000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 109.43 Mn |
| Dec 31, 2023 | 109.43 Mn |